SCHEMBL4237685

SCHEMBL4237685

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(N)cc2C)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.51
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 3/20 0.46
GAA P10253 3/20 0.46
FPR2 P25090 1/20 0.45
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTT P42858 1/20 0.40
C5 P01031 1/20 0.40
RAB9A P51151 2/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238631 0.87 MEN1 (0.52) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4228811 0.87 PKM (0.60) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4242160 0.86 PKM (0.46) PKMTAS1R3TAS1R1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL4235457 0.86 PKM (0.58) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4233459 0.85 PKM (0.57) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4229275 0.84 PKM (0.63) PKMTAS1R3TAS1R1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL4233431 0.84 PKM (0.56) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL5184118 0.84 PKM (0.53) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4235514 0.83 MEN1 (0.56) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4228260 0.83 PKM (0.54) PKMTAS1R3TAS1R1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2007071840-A2 COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF CEREP (FR) 2007-06-28 WO disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.